Lucid intends to use the proceeds "for general corporate purposes, which may include, among other things, capital expenditures and working capital." ...
at a purchase price of $2.05 per share of common stock (or per common stock equiva WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq ...
today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of an aggregate of 17,513,136 shares of its common stock ...
Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer immunotherapy ...